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The oestrogen receptor (ER) interacts with coactivator proteins to modulate genes central to breast tumour progression. Oestrogen
receptor is encoded for by two genes, ER-a and ER-b. Although ER-a has been well characterized, the role of ER-b as a prognostic
indicator remains unresolved. To determine isoform-specific expression of ER and coexpression with activator proteins, we
examined the expression and localisation of ER-a, ER-b and the coactivator protein steroid receptor coactivator 1 (SRC-1) by
immunohistochemistry and immunofluorescence in a cohort of human breast cancer patients (n¼150). Relative levels of SRC-1 in
primary breast cultures derived from patient tumours in the presence of b-oestradiol and tamoxifen was assessed using Western
blotting (n¼14). Oestrogen receptor-b protein expression was associated with disease-free survival (DFS) and inversely associated
with the expression of HER2 (P¼0.0008 and Po0.0001, respectively), whereas SRC-1 was negatively associated with DFS and
positively correlated with HER2 (Po0.0001 and Po0.0001, respectively). Steroid receptor coactivator 1 protein expression was
regulated in response to b-oestradiol or tamoxifen in 57% of the primary tumour cell cultures. Protein expression of ER-b and SRC-1
was inversely associated (P¼0.0001). The association of ER-b protein expression with increased DFS and its inverse relationship with
SRC-1 suggests a role for these proteins in predicting outcome in breast cancer.
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In breast cancer, genomic actions of oestrogen are mediated
through its receptor, leading to the transcription and translation of
genes relevant to tumour progression. The oestrogen receptor (ER)
is encoded by two genes, ER-a and ER-b, although the
predominant form is ER-a, ER-b protein has been reported in
30–70% of breast cancers (Omoto et al, 2002; Fleming et al, 2004a;
Palmieri et al, 2004). The role of ER-b in breast tumour
progression, however, remains controversial. Differential signal-
ling between ER-a and ER-b has been demonstrated with
oestrogen and tamoxifen at the AP1 response element in ER target
genes (Paech et al, 1997), suggesting that the ratio of ER-a to ER-b
may result in alternate gene regulation and could consequently be
important in determining the response to ER modulators, such as
tamoxifen.
Ex vivo clinical studies undertaken to elucidate the prognostic
significance of ER-b have, to date, been inconclusive. Early reports
on ER-b mRNA expression in breast cancer described significant
associations with axillary lymph node positivity and rate of
tumour recurrence while on endocrine therapy (Speirs et al,
1999a,b), lending credence to the hypothesis that ER-b is a poor
prognostic indicator. Oestrogen receptor-b protein expression,
however, has been associated with low tumour grade, negative
axillary node status and a positive response to endocrine treatment
(Jarvinen et al, 2000; Mann et al, 2001; Fleming et al, 2004a).
Furthermore, ER-b protein expression was recently related
to increased disease-free survival (DFS) and overall survival
(Nakopoulou et al, 2004).
The extent of ER gene regulation is influenced not only by the
ligand but also by the presence of specific coregulatory proteins,
present at rate limiting levels, which modulate transcription. Over
the past few years, a number of nuclear receptor interacting
proteins have been isolated using various screening strategies.
These include the p160 family of coactivator proteins, steroid
receptor coactivator 1 (SRC-1) and amplified in breast cancer 1
(AIB1), both of which have intrinsic histone acelyl-transferase
activity which enhance transcription by enabling access of
transcription factors and RNA polymerase II core machinery to
target DNA (Spencer et al, 1997; Liao et al, 2002). The relative
expression of coregulatory proteins has been associated with
tumour progression and the development of resistance to
endocrine therapies. There is little consensus however as to the
direction of these changes. Steroid receptor coactivator 1 and AIB1
mRNA levels have been associated with tumour progression;
however, studies investigating coactivator RNA expression and
resistance to ER modulators failed to demonstrate a significant
association (Murphy et al, 2000, 2002). Recent studies have
reported positive associations between AIB1 protein expression,
high tumour grade and coexpression with the coactivators p300/
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yCBP (Hudelist et al, 2003). We have previously described a positive
relationship between SRC-1 expression and resistance to endocrine
therapy (Fleming et al, 2004a) and have observed a significant
association between both SRC-1 and AIB1 and the proto-oncogene
HER2 (Fleming et al, 2004b).
We hypothesise that differences in expression and clinical
correlations of ER isoforms in human breast cancer may be related
to the altered response to the steroid environment and also the
local expression of coactivator proteins. We have therefore
examined the relationship between ER isoforms, ER-a and ER-b,
and the coactivator protein SRC-1 in patients who developed
disease recurrence.
MATERIALS AND METHODS
Patient population and clinical characteristics
A total of 150 breast carcinomas from patients who were diagnosed
between 1996 and 2002 and six specimens of histologically normal
breast tissue from patients undergoing reduction mammoplasties
were examined. All patients had stage I–II breast cancer at
presentation and were deemed free of distant metastases. All
patients received chemotherapy and tamoxifen (20mgday
 1) for a
maximum of 5 years. Tamoxifen was discontinued only in those
patients who suffered a relapse while on endocrine therapy. In
those patients who were ER negative, tamoxifen was prescribed on
the basis of the fact that they were progesterone receptor positive.
Those who received neoadjuvant chemo- or endocrine therapy
were not included.
Primary breast tumour cell cultures
Following ethical approval, breast tumour specimens were
obtained from 14 patients undergoing surgery for removal of a
histologically confirmed breast tumour. Approximately 1cm
3 of
solid tumour was taken by the pathologist from the excision biopsy
for cell culture, peripheral sections of which were removed and
confirmed to be tumour by standard haematoxylin and eosin.
Primary tumour epithelial cell cultures were prepared essentially
as previously described (Fleming et al, 2004a). In brief, epithelial
cells were extracted in HBSS without calcium or magnesium
(Gibco, Paisley, Scotland) supplemented with 1mM EDTA and 1mM
DTT for 40min and cultured in RPMI containing 5mgml
 1 insulin,
10mgml
 1 transferrin, 30nM sodium selinate, 10nM hydrocorti-
sone, 10nM b-oestradiol, 10mM Hepes, 2mM glutamine, 10% fetal
calf serum (wv
 1) and 5% ultroser G. To maximise cell
attachment, cells were grown on a growth factor-reduced Matrigel
matrix (BD Biosciences, San Jose, CA, USA) (60ngcm
 2). After
24h, cells were washed in PBS and placed in phenol-free, serum
and steroid-depleted MEM medium (Gibco) for 24h before
stimulation. Incubations were performed in the presence and
absence of b-oestradiol and 4-hydroxytamoxifen (4-OHT) (10
 8 M)
for 24h and harvested. Total protein was extracted using lysis
buffer (1% Ipegal, 0.5% deoxycholic acid, 0.1% SDS and 1  PBS)
with pefabloc (5mgml
 1).
Flow cytometry
Examination of primary breast cultures by staining with ethidium
bromide and flow cytometric analysis using a phycoerythrin (PE)-
labelled pan-leucocyte marker (CD45 RA and RO) confirmed cell
viability and epithelial origin of tumour cells as previously
described (Fleming et al, 2004a). Phenotypically distinct progeni-
tor and nonprogenitor epithelial cell populations within the
mammary epithelium were characterised. Flow cytometric analysis
was carried out using a PE-conjugated monoclonal mouse anti-
human EpCAM (epithelial specific antigen) antibody and FITC-
conjugated mouse anti-human CD227 (MUC1) monoclonal mouse
antibody (BD Biosciences). Biopotent progenitors (EpCAM
þ
MUC1
 ), which can generate both luminal and myoepithelial
cells, were found to represent 51.9% of the epithelial specific
antigen positive cell population, whereas the luminal restricted
progenitor (EpCAM
þ MUC
þ) were found to represent 48.1%.
Immunohistochemistry
Thick tissue sections (5mm) were cut from paraffin-embedded
breast tumour tissue and reduction mammoplasty blocks and
mounted on Superfrost Plus slides (BDH, Poole, UK). Sections
were dewaxed, rehydrated and washed in PBS. Endogenous
peroxidase was blocked using 3% hydrogen peroxidase in PBS
for 10min. Antigen retrieval was performed by immersing sections
in 0.6 M citrate buffer and microwaving on high power for 7min.
Immunohistochemistry was carried out using the Vectastain Elite
kit (Vector Labs, Burlingame, CA, USA) according to the
manufacturer’s instructions. Briefly, sections were blocked in
serum for 90min. Sections were incubated with primary anti-
bodies; rabbit anti-human ER-a (1mgml
 1), goat anti-human SRC-
1( 1mgml
 1) (Santa Cruz, CA, USA) and mouse anti human ER-b
(one in 20 in PBS) (Serotec, Oxford, UK) – for 60min at room
temperature. Antibodies for ER-b are directed against the wild-
type ER-b, recognising the ER-b1 isoform of the protein. Sections
were subsequently incubated with corresponding biotin-labelled
secondary antibody (one in 2000) for 30min, followed by
peroxidase-labelled avidin–biotin complex. Sections were devel-
oped in 3,3-diaminobenzidine tetrahydrochloride (DAB) and
counterstained with haematoxylin. Negative controls were per-
formed using matched IgG controls (Dako, Denmark). Sections
were examined under a light microscope. Immunostained slides
were scored for ER-a, ER-b and SRC-1 using the Allred scoring
system, as previously described (Harvey et al, 1999).
Immunofluoresent microscopy
Breast cancer sections prepared as above were used for immuno-
fluorescent studies. Slides were incubated in goat serum (ER-a)o r
sheep serum (ER-b) for 60min. Rabbit anti-human ER-a
(10mgml
 1 in 10% human serum) or mouse anti-human ER-b
(1:2 dilution with PBS in 10% human serum) was placed on each
slide for 90min. The sections were rinsed in PBS and incubated
with the corresponding secondary fluorochrome-conjugated anti-
body (one in 100) (Sigma-Aldrich, Steinheim, Germany) for
60min. The slides were rinsed in PBS and blocked in rabbit
serum for 90min and subsequently washed again with PBS. Each
slide was incubated with goat anti-human SRC-1 (10mgml
 1 with
PBS in 10% human serum) for 90min. The slides were incubated
with the corresponding fluorochrome-conjugated antibody (one in
100) for 60min. Sections were rinsed in PBS and mounted using
fluorescent mounting media (DAKO, Denmark). Sections were
examined under a fluorescent microscope. Negative controls were
performed using matched IgG.
Western blotting
Proteins (100mg) were resolved on a 12% polyacrylamide gel at
110V for 120min and then transferred to a nitrocellulose
membrane (250mA for 60min). Membranes were incubated for
60min in blocking buffer (5% nonfat dry milk, 0.1% Tween in
PBS) at room temperature and subsequently with primary
antibody, goat anti-rabbit SRC-1 (2mgml
 1), in blocking buffer
overnight at 41C. The membranes were washed prior to incubation
with the corresponding secondary antibody (Santa Cruz Biotech-
nology Inc.) (one in 2000) in blocking buffer for 60min at room
temperature. The membranes were washed and developed with
intensified luminescence (Pierce).
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Variables analysed included patient age, tumour size, tumour
grade, HER2 status and axillary node status. A recurrence was
defined as any local (chest wall) or systemic (visceral or bone
metastasis) recurrence during the follow-up period.
Statistical analysis
Fisher’s exact test was used in the comparison of two proportions
throughout or equivalently to test for association in 2 2 tables.
Kaplan–Meier estimates of survival functions were computed and
the Wilcoxon test was used to compare survival curves. A Cox
proportional hazards model was used to find significant predictors
of disease-free survival (DFS). The predictors included in the
model were: age, type of operation, axillary status, size of tumour,
grade of tumour, AIBI, ER-a, ER-b and SRC-1. A stepwise
procedure was used to find the best model. SAS statistical software
(SAS Institute Inc., 1989) was used to perform these analyses.
RESULTS
Localisation of ER-a, ER-b and SRC-1 in human breast
cancer
Oestrogen receptor-a, ER-b and the SRC-1 were localised in
human breast tissue from patients with primary breast tumours
and from patients undergoing normal reduction mammoplasties.
Patient characteristics are given in Table 1. The median follow-up
was 27 months.
Both ER isoforms were localised to the nuclei of primary breast
tumour epithelial cells (Figure 1A). However, while ER-a was
expressed almost exclusively in the nuclei of tumour cells, distinct
cytoplasmic expression of ER-b was observed. Oestrogen receptor-
b, but not ER-a, was found to be expressed in normal tissue
surrounding the tumour and in tissue sections from normal
reduction mammoplasties. Steroid receptor coactivator 1 was
localised to the nuclei of breast tumour epithelial cells, but was not
observed in normal breast tissue (Figure 1B). Colocalisation of
both ER-a and ER-b with SRC-1 in breast tumour epithelial cells
was confirmed using immunofluorescence (Figure 1C).
ER-a and ER-b were found to be expressed in 82 and 58% of
breast tumour patients, respectively, whereas SRC-1 was detected
in 19% of breast tumours (Table 1). Oestrogen receptor-a and ER-
b were coexpressed in 46.6% of tumours. Oestrogen receptor-a and
SRC-1 were coexpressed in 17.3%, whereas ER-b and SRC-1 were
both expressed in 4.6% of breast tumours. There was no significant
correlation observed between ER-a protein expression and SRC-1
(P¼0.4130), however, ER-b was found to be inversely associated
with the steroid receptor coactivator (P¼0.0001).
Correlation of ER-a, ER-b and SRC-1 with clinical variables
Associations between the qualitative expression of ER-a, ER-b and
SRC-1 and clinicopathological parameters were examined. No
relationship between the expression of the ER isoforms was
observed in relation to patient age, tumour size, histological grade
and axillary node status (Table 1). Steroid receptor coactivator 1
was found to positively associate with tumour size (Po0.0001),
and HER2 status (Po0.0001), whereas ER-b inversely associated
with HER2 expression (Po0.0001) (Table 1).
From Kaplan–Meier estimates of survival, ER-b protein
expression was found to be significantly associated with DFS
(P¼0.0008), conversely SRC-1 significantly associated with
disease recurrence (Po0.0001), (Figure 2). Using a Cox propor-
tional hazards model, significant predictors of DFS were identified.
The final model included SRC-1 and axillary node status as
significant predictors (Po0.0001 and P¼0.0193, respectively).
Although ER-b was also a significant predictor of DFS, it is not
required in the model in the presence of SRC-1, due to the strong
association between ER-b and SRC-1 expressions.
Table 1 Associations of ER-a, ER-b and SRC-1 with clinicopathological parameters, comparisons with Fishers exact test
Total ER-a positivity (%) P-value ER-b positivity (%) P-value SRC-1 positivity (%) P-value
No. of patients 150 123 (82%) — 87 (58%) — 28 (19%) —
Patient age (years)
p50 69 56 (81%) 35 (51%) 21 (30%)
450 81 67 (83%) 0.8338 52 (64%) 0.1009 7 (9%) 0.0007
Tumour size (mm)
p35 107 85 (79%) 67 (63%) 9 (8%)
435 43 38 (88%) 0.2448 20 (47%) 0.0991 19 (44%) o0.0001
Histological grade
Grade 3 74 64 (86%) 46 (62%) 17 (23%)
Non-Grade 3 76 59 (78%) 0.2030 41 (54%) 0.3256 11 (14%) 0.2120
Node status
Node positive 94 78 (83%) 53 (56%) 20 (21%)
Node negative 56 45 (80%) 0.8264 34 (61%) 0.6133 8 (14%) 0.3869
HER-2-neu expression
Her-2-neu positivity 38 34 (89%) 10 (26%) 16 (42%)
Her-2-neu negativity 112 89 (79%) 0.2234 77 (69%) o0.0001 12 (11%) o0.0001
SRC-1 expression
SRC-1 positivity 28 25 (89%) 7 (25%) — —
SRC-1 negativity 122 98 (80%) 0.4130 80 (66%) 0.0001 —
Recurrences
Recurrence 29 26 (90%) 7 (24%) 26 (90%)
Nonrecurrence 121 97 (80%) 0.2911 80 (66%) o0.0001 2 (2%) o.0001
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The ability of SRC-1 protein to be regulated by oestrogen and the
selective ER modulator, tamoxifen (4-OHT), was examined in
primary breast cell cultures derived from patient tumours, median
follow-up 4 months (n¼14) (Figure 3). Basal levels of SRC-1 were
detected in all cultures. Treatment with oestrogen induced an
increase in SRC-1 protein expression, compared to basal levels, in
28% of tumour cell cultures, whereas tamoxifen induced a
reduction in SRC-1 expression in a similar number of breast
ER- ER- SRC-1
ER-
ER- ER- SRC-1
SRC-1
IgG Control IgG Control IgG Control
Colocalisation
ER- SRC-1 Colocalisation
A
B
C
Figure 1 ER-a, ER-b and SRC-1 protein expression in paraffin-embedded invasive breast carcinoma and normal breast tissue specimens. (A)
Immunohistochemical localisation of ER-a, ER-b and SRC-1 ( 200) in primary breast cancer counterstained with haematoxylin and matched IgG controls.
(B) ER-a, ER-b and SRC-1, ( 200) protein expression in normal breast tissue. (C) Immunofluorescent colocalisation of ER-a with SRC-1 ( 200) and ER-b
with SRC-1 ( 200) invasive breast carcinoma.
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negative increased protein expression of SRC-1 in response to
treatment with b-oestradiol.
The relative response to oestrogen and tamoxifen treatment was
examined in relation to the patient clinical characteristics. Of
interest, tumours that upregulated SRC-1 protein expression in
response to oestrogen were also found to be HER2 positive and
those that reduced SRC-1 expression in the presence of tamoxifen
were HER2 negative (Table 2).
DISCUSSION
The prognostic significance of ER-b protein expression in human
breast cancer remains controversial. Altered response to oestrogen
and ER modulators between ER-a and ER-b in relation to receptor
DNA binding, activation of target genes and in vivo tumour
formation has been described (Paech et al, 1997; Paruthiyil et al,
2004), leading to the possibility that the two ER isoforms may have
distinct roles in disease progression. Ex vivo studies examining the
expression of ER-b mRNA in relation to clinicopathological
parameters have described associations between ER-a and ER-b
coexpression and axillary node positivity (Speirs et al, 1999a), and
in a limited series, between ER-b mRNA and resistance to
endocrine treatment (Speirs et al, 1999b). However, at the protein
level using antibodies directed against the NH2-terminal region of
ER-b, detecting both full-length ER-b (ER-b1) and various COOH-
terminal truncated isoforms, Fuqua et al (2003) found no
correlation between ER-b expression and tumour grade, prolifera-
tion, S-phase fraction or DNA ploidy, while others found ER-b
status to be a significant predictor of response to endocrine
therapy (Mann et al, 2001; Fleming et al, 2004a). Furthermore,
reductions in ER-b protein expression have been associated with
the development of an invasive phenotype (Skliris et al, 2003).
These studies raise the possibility that ER-b may function as a
tumour suppressor and that loss of ER-b could promote
tumourogenesis. In this study using antibodies directed against
the COOH-terminal, we examined the expression of wild-type ER-
b (ER-b1) in relation to established clinical parameters of breast
cancer. We found a positive association between ER-b protein
expression and DFS, furthermore, a significant inverse relationship
between ER-b and the proto-oncogene HER2 was also observed.
A role for nuclear coregulatory proteins in ER-mediated
transactivation of target genes has been established. We and
others have described altered recruitment of coactivator proteins
to the ER in the presence of oestrogen and ER modulators (Bai and
Giguere, 2000; Margeat et al, 2003; Fleming et al, 2004a). We have
previously observed that SRC-1 protein expression was associated
with resistance to endocrine therapy (Fleming et al, 2004a) and the
growth factor receptor HER2 (Fleming et al, 2004b). Here, we
describe a significant inverse association between SRC-1 and DFS.
When we related ER-b and SRC-1 protein expression, we found a
significant inverse relationship, suggesting that the role of ER-b as
a good prognostic indicator may be due, at least in part, to low
expression levels of the p160 coactivator SRC-1. We examined the
ability of oestrogen and the ER modulator, tamoxifen, to regulate
SRC-1 protein expression in primary breast cell cultures derived
from patient tumours and found that approximately 28% of
cultures increased protein expression of SRC-1 in response to
oestrogen, whereas the same percentage, but different patient
group, reduced SRC-1 in the presence of tamoxifen. Of interest one
of the tumours that upregulated SRC-1 protein expression in
response to b-oestradiol was ER negative. This may reflect
oestrogen functioning in a nongenomic fashion, independently
of the nuclear receptor ER. Oestrogen actions in ER-negative
breast cell lines have previously been described (Filardo et al,
2000).
When response to endocrine environment was related to clinical
characteristics, we found that those tumours which upregulated
SRC-1 in the presence of oestrogen were all HER2-positive
tumours and conversely those that could downregulate SRC-1 in
response to tamoxifen were HER2 negative. The relationship
between SRC-1 response to the steroid environment and HER2
status is an interesting one, as p160 proteins are known to be
phosphorylated via the MAP kinase pathway (Font de Mora and
Brown, 2000; Rowan et al, 2000). Taken together, these data
provide further evidence of the proposed crosstalk between growth
factor receptor pathways and activation of steroid receptor
coactivator proteins (Johnston et al, 2003; Osborne et al, 2003).
The observation that SRC-1 expression is strongly associated
with the development of recurrence and a reduced DFS requires
validation in a large cohort of breast cancer patients to establish its
potential as a meaningful prognostic marker in breast cancer. The
association of ER-b protein expression with increased DFS and its
inverse relationship with the coregulatory protein SRC-1 suggests a
significant role for these proteins in determining outcome in breast
cancer.
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Figure 2 Kaplan–Meier estimates of disease-free survival (DFS). (A)
Disease-free survival according to ER-b expression and (B) according to
SRC-1 expression.
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